Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches

Cogorno, Ludovica; Formisano, Elena; Vignati, Andrea; Prigione, Amalia; Tramacere, Antonio; Borgarelli, Consuelo; Sukkar, Samir Giuseppe; Pisciotta, Livia

doi:10.1016/j.livres.2023.08.005

Cited by 4 publications

(2 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the intake of VSL#3 ® could not improve the endothelial function and inflammation in patients with NAFLD [ 51 ]. Probiotic treatment has been widely used in the treatment of NAFLD; therefore, the viability and safety of new probiotic strains should be well-evaluated for the treatment and management of NAFLD in clinical studies to reduce uncertainty [ 52 ]. Additionally, further investigations could focus on the biochemical indexes of NAFLD-related diseases, like cardiovascular diseases, to reduce the risk of having other complications in patients with NAFLD.…”

Section: Probiotics and Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Updated Insights into Probiotics and Hepatobiliary Diseases

Xu,

Zhang,

Tang

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Hepatobiliary diseases have a high prevalence worldwide, with a wide range of diseases involved in the liver and biliary system. Modifications in gut microbiota have been proven to have an association with unbalanced intestinal homeostasis and the dysfunction of host metabolism and the immune system, which can be the risk factors for many hepatobiliary diseases, such as nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), nonalcoholic fatty steatohepatitis (NASH), hepatitis, cirrhosis, hepatocellular carcinoma (HCC) and cholestasis, as well as infection due to liver transplantation. Probiotics are commonly used gut microbiota-targeted strategies to treat dysbiosis and intestinal dysfunction, as well as the gut–liver axis, which can enhance the effectiveness of probiotics in the management of liver diseases. Recent studies have explored more potential single or mixed strains of probiotics, and bioinformatics methods can be used to investigate the potential mechanisms of probiotics on liver diseases. In this review, we summarize the preclinical and clinical studies on the role of probiotics in hepatobiliary diseases from 2018 to 2023, revealing the possible mechanism of probiotics in the treatment of hepatobiliary diseases and discussing the limitations of probiotics in treating hepatobiliary diseases. This review provides updated evidence for the development of probiotic products, exploration of new probiotic strains, and support for clinical studies. Further studies should focus on the safety, viability, and stability of probiotics, as well as medication dosage and duration in clinical practice.

show abstract

Section: Probiotics and Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Updated Insights into Probiotics and Hepatobiliary Diseases

Xu,

Zhang,

Tang

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…When fat accumulates excessively within the liver, exceeding 5% of its weight, it is defined as fatty liver. , Fatty liver is divided into two major types: one is an alcoholic fatty liver disease (AFLD), known for its association with prolonged and immoderate alcohol intake. The second type is a metabolic dysfunction associated fatty liver disease (MAFLD), linked to diverse factors including stress, obesity, genetic susceptibility, and metabolic syndrome. − The presence of fatty liver disease is linked to an elevated risk of negative consequences, encompassing liver-related health issues, cardiovascular ailments, and mortality. − As depicted in Figure a, there is a 15% to 20% probability for individuals with MAFLD to develop into metabolic dysfunction-associated steatohepatitis (MASH). In approximately 10% to 20% of instances involving MASH, there is a potential for subsequent progression into cirrhosis, and in more severe cases, the development of HCC may also occur. , …”

Section: Types Of Liver Diseasesmentioning

confidence: 99%

Emerging mRNA Technology for Liver Disease Therapy

Wang,

Fang,

Luo

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Liver diseases have consistently posed substantial challenges to global health. It is crucial to find innovative methods to effectively prevent and treat these diseases. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases. In this review, we start by providing a detailed introduction to the mRNA technology. Afterward, we highlight types of liver diseases, discussing their causes, risks, and common therapeutic strategies. Additionally, we summarize the latest advancements in mRNA technology for the treatment of liver diseases. This includes systems based on hepatocyte growth factor, hepatitis B virus antibody, left−right determination factor 1, human hepatocyte nuclear factor α, interleukin-12, methylmalonyl-coenzyme A mutase, etc. Lastly, we provide an outlook on the potential of mRNA technology for the treatment of liver diseases, while also highlighting the various technical challenges that need to be addressed. Despite these difficulties, mRNA-based therapeutic strategies may change traditional treatment methods, bringing hope to patients with liver diseases.

show abstract

An underutilized bean: hyacinth bean [Lablab purpureus (L.) sweet]: bioactive compounds, functional activity, and future food prospect and applications

Zhou,

Wang,

Zhang

et al. 2024

J Sci Food Agric

View full text Add to dashboard Cite

Hyacinth bean [Lablab purpureus (L.) Sweet], a plant belonging to the leguminous family and traditionally used for medicinal purposes in China, is a valuable resource with a wide range of health benefits. This review examines the bioactive compounds, health‐promoting properties and functional food potential of hyacinth bean, highlighting its role in protecting against metabolic diseases and the underlying molecular mechanisms. According to existing research, hyacinth bean contains a diverse array of bioactive compounds, Consumption of hyacinth beans and hyacinth bean‐related processed food products, as well as their use in medicines, is associated with a variety of health benefits that are increasingly favoured by the scientific community. In light of these findings, we posit that hyacinth bean holds great promise for further research and food application. © 2024 Society of Chemical Industry.

show abstract

Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches

Cited by 4 publications

References 137 publications

Updated Insights into Probiotics and Hepatobiliary Diseases

Updated Insights into Probiotics and Hepatobiliary Diseases

Emerging mRNA Technology for Liver Disease Therapy

An underutilized bean: hyacinth bean [Lablab purpureus (L.) sweet]: bioactive compounds, functional activity, and future food prospect and applications

Contact Info

Product

Resources

About